U.S. FDA Issues Approvable Letter for Requip XL Extended Release Tablets
LONDON, UK, 10 December 2007-- SkyePharma PLC today announces that the United States Food and Drug Administration (FDA) has issued an approvable letter for GlaxoSmithKline's Requip XL Extended Release tablets. An approvable letter is an official notification from the FDA that contains conditions that must be satisfied prior to obtaining final U.S. marketing approval.
Requip XL is a once-daily oral dopamine agonist developed for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The new Requip XL formulation uses SkyePharma's patented GEOMATRIX technology and is designed to provide a steady rate of absorption in the body to help reduce daily blood plasma fluctuations. GSK is committed to working with the FDA to address any questions they have and evaluate the best way forward.
Requip XL is approved in eight countries in Europe and a mutual recognition procedure was successfully completed on 27 November 2007, in 17 additional European countries. This step should result in approval of Requip XL and launches in these countries from the first quarter of 2008 onwards.
For further information please contact:
SkyePharma
PLC
Frank
Condella
+44 20 7491 1777
Ken Cunningham
Peter Grant
Financial Dynamics (UK
Enquiries)
David
Yates
+44 20 7831 3113
Deborah Scott
Trout Group (US
Enquiries)
Christine Labaree
+1 617 583 1308
Seth Lewis
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma
develops new formulations of known molecules to provide a clinical
advantage and life-cycleextension. The Company has eleven approved
products in the areas of oral, inhalation and topical
delivery. The Group's products are marketed throughout the
world by leading pharmaceutical companies. For more
information, visit www.skyepharma.com
About GlaxoSmithKline
Requip XL was developed and is marketed by GlaxoSmithKline,
one of the world's leading research-based pharmaceutical and
healthcare companies. More information on GlaxoSmithKline is
available at the company's website at www.gsk.com.
Posted: December 2007
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.